Latest News

AstraZeneca opens a biomethane facility in the UK to reduce emissions

AstraZeneca opened an organic waste biogas plant that will power all its drug production and research in Britain by the end this year.

The plant will be operated under a 15-year contract between AstraZeneca, a UK biomethane producer, and Future Biogas. It will provide 100 gigawatt-hours (GW) per year of renewable energy for AstraZeneca’s three R&D sites and manufacturing facilities in the country. This is equivalent to 20% its global gas consumption.

Why it's important

Cost-cutting is a priority for many big companies, and the return of U.S. president Donald Trump to the White House has changed the focus on fossil fuels.

The government of Keir starmer, the British Prime Minister, is pushing for the decarbonisation of the nation's electricity network through private investment.

The UK government has not provided any subsidy to AstraZeneca for its new plant in Lincolnshire (east England).

The company's switch to renewables in the UK is part a larger commitment to use 100 percent renewable energy globally by the year end.

The commitment of the company to achieve net zero emissions in 2045 by 2020, which was set in 2010, also depends on suppliers who use green power.

CONTEXT

AstraZeneca signed a long-term agreement with Vanguard Renewables in 2023, which enabled the company to switch from natural gas to biogas and reduce its emissions at its U.S. manufacturing and research sites.

The company wants to reduce its greenhouse gas emissions by 98% from 2015, compared with a baseline of 2015.

Although Danish drugmaker Novo Nordisk set similar targets for reducing its carbon footprint, the company said earlier this year that its emissions will continue to rise through the decade due to the increased production of Wegovy, its blockbuster weight loss drug. (Reporting and editing by Barbara Lewis; Maggie Fick)

(source: Reuters)